Pharmaceutical Translation Services for FDA, EMA, and ICH Regulatory Submissions

ICH CTD Regulatory Dossier Translation — FDA, EMA, and PMDA

The ICH Common Technical Document (CTD) is the unified regulatory submission format accepted by all ICH member regulatory authorities: FDA (US), EMA (EU), PMDA (Japan), Health Canada, TGA (Australia), and others. Understanding the CTD structure is fundamental to pharmaceutical regulatory translation.

The five CTD modules:

Module 1 — Administrative information (region-specific): Each regulatory authority has its own Module 1 requirements in their national language. For EMA, Module 1 includes the Application Form in English. For PMDA, Japanese Module 1 documentation is required.

Module 2 — CTD summaries: The Quality Overall Summary (QOS), Nonclinical Overview and Written and Tabulated Summaries, and the Clinical Overview, Clinical Summary, and Literature References. Module 2 is often required in full translation for regional submissions where the regulatory authority operates in a language other than the submission language.

Module 3 — Quality (CMC — Chemistry, Manufacturing, and Controls): Drug substance and drug product manufacturing data, analytical methods, stability data, and container/closure information. CMC translation requires medicinal chemistry and analytical chemistry expertise.

Module 4 — Nonclinical study reports: Pharmacology, pharmacokinetics, and toxicology study reports. Nonclinical translation requires pharmaceutical sciences and toxicology background.

Module 5 — Clinical study reports: Individual study reports, patient data tabulations, and case narratives. CSR translation is the most clinically complex module, requiring clinical medicine and biostatistics credentials.

EMA centralized procedure — the 24-language requirement: Upon grant of a Marketing Authorization through the EMA centralized procedure, the Summary of Product Characteristics (SmPC), package leaflet, and product labeling must be available in all 24 official EU languages. This creates a translation program of substantial scope for every successful EU drug approval. The SmPC and package leaflet must follow EMA QRD (Quality Review of Documents) template formats and use WHO INN names for the active substance.

PMDA — Japanese regulatory translation: Japan's PMDA follows the J-CTD format (Japanese adaptation of the ICH CTD) with Japan-specific Module 1 requirements. The Japanese Package Insert (iyakuhin no hyojou) requires Japanese pharmaceutical translation by translators with PMDA submission experience.

Clinical Trial Translation — ICH GCP E6(R2) Compliance

Clinical trial documentation translation requires compliance with ICH E6(R2) Good Clinical Practice Guidelines. The specific standard governing informed consent is ICH E6(R2) Section 4.8.10, which requires that consent forms be "in a language understandable to the subject" — making ICF translation a GCP compliance requirement with ethics committee (IRB/IEC) oversight in each country.

Core clinical trial documents requiring translation:

• Protocol and amendments: The governing document for trial conduct — must be translated for country-specific ethics committee submissions and investigator training. Inclusion/exclusion criteria, dosing regimens, safety monitoring rules, and statistical analysis specifications must be translated with precision.
• Informed Consent Form (ICF): The most critical GCP translation. Must be at a reading comprehension level appropriate for the trial population. Ethics committees in each country review and approve the local-language ICF before subject enrollment.
• Investigator's Brochure (IB): Background document on the investigational medicinal product. Translated for country regulatory authority submissions and investigator qualification.
• Case Report Form (CRF): The data capture instrument. CRF translation must maintain field-level consistency with the protocol definitions and adverse event coding conventions.
• Clinical Study Report (CSR): Structured per ICH E3 guidelines. CSRs may contain hundreds of pages of clinical data, adverse event narratives, and statistical output. Adverse event terminology must be rendered using correct MedDRA Preferred Terms in the target language.
• Development Safety Update Report (DSUR): Annual safety report for investigational products during clinical development, submitted to regulatory authorities in each country where trials are ongoing.

Pharmacovigilance Document Translation — PSURs, ICSRs, and RMPs

Once a pharmaceutical product is approved, pharmacovigilance obligations create continuous, mandatory translation demand across the entire market life of the drug. This is the highest-volume, most recurring pharmaceutical translation segment for approved products.

Individual Case Safety Reports (ICSRs). Adverse event reports submitted to regulatory authorities. ICSRs for the EU market are submitted to EudraVigilance (the EMA's pharmacovigilance database). National competent authorities may additionally require ICSRs in the national language. Serious unexpected adverse reactions have a 15-day ICSR reporting deadline under EMA Regulation 726/2004 — making ICSR translation a genuinely urgent workflow.

Periodic Safety Update Reports (PSURs). Comprehensive periodic safety reviews submitted to EMA and national competent authorities on fixed regulatory timelines. PSURs incorporate clinical trial data, post-marketing adverse event data, and benefit-risk assessment. PSUR sections requiring translation vary by regulatory authority and product approval conditions.

Risk Management Plans (RMPs). Required by EMA for all new Marketing Authorizations, the RMP details a product's known and potential risks and risk minimization measures. The RMP is submitted as part of the MAA and updated periodically post-approval.

Direct Healthcare Professional Communications (DHPCs). Important safety communications sent to prescribers and pharmacists about a drug's risks. DHPCs must be approved by national competent authorities and are typically required in the national language of each EU member state.

MedDRA terminology in pharmacovigilance translation: All adverse event terminology in ICSRs, PSURs, and CSRs must use MedDRA (Medical Dictionary for Regulatory Activities) Preferred Terms in the target language. MedDRA Preferred Terms have specific meanings within the MedDRA hierarchy; freely translated adverse event terms will not match the coded terms in regulatory databases. TheWordPoint applies MedDRA terminology to all pharmacovigilance document translation.

GMP Manufacturing Documentation Translation

In essence, pharma translation is a type of business document translation. However, it is highly technical and demands the highest level of attention to detail from medical professionals. Good Manufacturing Practice (GMP) compliance under FDA 21 CFR Parts 210/211, EU GMP guidelines, and ICH Q10 requires that manufacturing documentation be in a language that manufacturing personnel understand — creating significant translation requirements for pharmaceutical manufacturers with multinational production sites.

Standard Operating Procedures (SOPs): Every manufacturing operation from raw material receipt to finished product release has a governing SOP. GMP auditors require that SOPs be in the working language of the personnel following them. Multi-site global manufacturers require SOPs translated across all production language environments.

Batch Manufacturing Records (BMRs): The primary GMP record for each production batch. BMR translation must maintain precise alignment with the manufacturing process as documented in the approved regulatory submission.

Validation protocols and reports (IQ/OQ/PQ): Installation Qualification, Operational Qualification, and Performance Qualification documentation for equipment, processes, and cleaning procedures. Validation documentation translation requires a chemical engineering and pharmaceutical manufacturing background.

CMC documentation (Module 3 CTD): Chemistry, Manufacturing, and Controls section translation for regulatory submissions covers drug substance synthesis, manufacturing process development, analytical methods, and stability data.

Quality system documentation: Change control records, deviation management, CAPA (Corrective and Preventive Action) documentation, and supplier qualification records that must be auditable in the local language of the manufacturing site.

Drug Labeling Translation — WHO INN Names and Regulatory Requirements

Pharmaceutical labeling translation is more technically constrained than any other document type in the pharmaceutical category because the active substance must always be identified by its WHO International Nonproprietary Name (INN) — the standardized generic drug name used across all markets and all languages.

WHO INNs are language-neutral identifiers: the same INN is used in English, German, French, Spanish, Japanese, and all other languages. However, INN names must be correctly distinguished from brand names and chemical names, and the INN format must be preserved exactly as established by WHO. EU drug labeling under EU QRD templates requires INN names to be present in specific label positions and in a specific format relative to the brand name.

Labeling document types requiring translation:

Prescribing Information (PI) / Summary of Product Characteristics (SmPC) for healthcare professionals, Package Insert / Patient Information Leaflet (PIL) for patients (both required in all 24 EU official languages for EMA-approved products), secondary packaging text (carton, blister, vial), immediate container label (bottle, ampoule, syringe label), and medication guides for high-risk products (required by FDA for certain drug classes).

Professional Translators Providing Pharmacy Translation Services

If you are looking for a professional Spanish translation for pharmaceutical work, only a native Spanish-speaking translator with verified expertise in the pharmaceutical industry will be assigned to your project — ensuring the translation quality and domain accuracy your content demands.

Offering translation services in 80+ languages, TheWordPoint focuses on human translation for pharmacy and pharmaceutical needs because it is essential that every translator assigned to a pharmaceutical project has a professional background in the field. This ensures that all terminology, protocols, and instructions are accurately translated and correctly localized for the target market.

Pharmaceutical translation services require more than linguistic proficiency — they demand in-depth knowledge of the industry. Our pharmaceutical translators are not only fluent in the source and target languages but also thoroughly versed in medical and scientific concepts, regulatory frameworks, and industry standards. This combination of expertise ensures that translations are accurate, culturally appropriate, and fully compliant with applicable pharmaceutical guidelines.

In the pharmaceutical industry, the ultimate purpose of translation is patient safety — ensuring that every person receives accurate, clearly communicated information about medications, dosages, warnings, and treatments. From drug labeling to clinical trial documentation, high-quality human translation prevents the misunderstandings and mistranslations that can lead to serious adverse outcomes.

Advances in technology have transformed the translation industry. Computer-Assisted Translation (CAT) software, translation memory systems, and terminology management tools improve efficiency, accelerate turnaround times, and maintain consistency across large projects. However, human expertise remains irreplaceable in pharmaceutical translation, where precision, regulatory knowledge, and contextual judgment cannot be automated.

When machine translation is applied without adequate human oversight, critical details can be missed or mistranslated — with consequences that may be irreversible. While automated tools can handle general content, pharmaceutical translation and immunization record translation must be completely error-free. A single mistranslation in a clinical trial document, a drug warning, or a dosage instruction can expose organizations to legal liability, delay drug approval, and — most critically — cause direct harm to patients. This is why TheWordPoint never relies on machine translation alone for pharmaceutical projects.

How Pharmaceutical Translation Works at TheWordPoint

• Identify regulatory authority and CTD module. FDA, EMA, PMDA, Health Canada, or national competent authority? Which CTD module? SmPC/PIL or GMP SOP? Each destination determines required translator credentials and delivery format.
• Submit with regulatory context. Upload at thewordpoint.com/business-free-quote. Provide: regulatory authority, CTD module number, document type, target languages, submission deadline, and any existing glossaries or prior translation memories.
• Project scope confirmed. CTD structure assessed, word volume calculated, regulatory timeline integrated. Fixed delivery dates confirmed relative to your submission deadline.
• Credentialed translator assigned. PharmD for SmPC, labeling, and pharmacovigilance. Medicinal chemistry PhD for CMC. Biostatistics credentials for CSR statistical sections. CRA credentials for GCP trial documents.
• Translation with MedDRA, INN, and QRD verification. MedDRA adverse event Preferred Terms applied in target language. WHO INN names correctly handled in labeling. EMA QRD template structure maintained in SmPC/PIL. Independent pharmaceutical reviewer checks before delivery.
• Delivery in regulatory format. Word, PDF, eCTD-compatible, or required format. Terminology glossary and translation memory retained for future amendments and line extension submissions.